Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Mariarosa Fava"'
Autor:
Marco Fiorillo, Elena Ricci, Mariarosa Fava, Camilla Longobucco, Federica Sotgia, Pietro Rizza, Marilena Lanzino, Daniela Bonofiglio, Francesca Luisa Conforti, Stefania Catalano, Ines Barone, Catia Morelli, Saveria Aquila, Michael P. Lisanti, Diego Sisci
Publikováno v:
Cells, Vol 12, Iss 24, p 2777 (2023)
Tamoxifen-resistant breast cancer cells (TamR-BCCs) are characterized by an enhanced metabolic phenotype compared to tamoxifen-sensitive cells. FoxO3a is an important modulator of cell metabolism, and its deregulation has been involved in the acquisi
Externí odkaz:
https://doaj.org/article/a318d65fff1b4bb8820e166359d731bb
Autor:
Ida Perrotta, Michele Pellegrino, Mariarosa Fava, Luca Frattaruolo, Elena Claire Ricci, Diego Sisci, Marianna Greco, Francesca Giordano, Antonella Leggio, Anna Rita Cappello, Alessandra Comandè, Alessandra Nigro, Catia Morelli, Marzia De Santo, Luigi Pasqua, Ilaria Ester De Napoli
Publikováno v:
Cancers, Vol 12, Iss 2709, p 2709 (2020)
Cancers
Volume 12
Issue 9
Cancers
Volume 12
Issue 9
A mesoporous silica-based nanodevice bearing the antineoplastic drug bortezomib (BTZ), whose release is triggered in acidic environment and grafted with folic acid (FOL) as a targeting function (FOL-MSN-BTZ) was tested on folate receptor overexpressi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03fa7c86ba6193b791ab822d136a39d2
https://www.mdpi.com/2072-6694/12/9/2709
https://www.mdpi.com/2072-6694/12/9/2709
Autor:
Elena Ricci, Mariarosa Fava, Pietro Rizza, Michele Pellegrino, Daniela Bonofiglio, Ivan Casaburi, Marilena Lanzino, Cinzia Giordano, Rosalinda Bruno, Rosa Sirianni, Ines Barone, Diego Sisci, Catia Morelli
Publikováno v:
Cancers
Cancers, Vol 14, Iss 214, p 214 (2022)
Cancers; Volume 14; Issue 1; Pages: 214
Cancers, Vol 14, Iss 214, p 214 (2022)
Cancers; Volume 14; Issue 1; Pages: 214
Simple Summary Tamoxifen is a mainstay of adjuvant treatment for estrogen receptor α-positive (ERα+) breast tumors, which account for over 70% of all the diagnosed breast malignancies. Unfortunately, ~30% of patients initially responding to the the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb7c7e1e9c46b12240f0c827c455d64e
https://doi.org/10.3390/cancers14010214
https://doi.org/10.3390/cancers14010214